Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Martin Filipits et al.|Annals of Oncology|2013Cited by 403
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialMeinolf Karthaus, Peter Reichardt, Albrecht Kretzschmar et al.|Annals of Oncology|2005Cited by 223
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, Christoph Zielinski, Rupert Bartsch et al.|Breast Cancer Research and Treatment|2009Cited by 120
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesRupert Bartsch, G. Steger, Anna S. Berghoff et al.|British Journal of Cancer|2011Cited by 77
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH projectValter Torri, Marina Elena Cazzaniga, Eva Ciruelos et al.|Cancer Chemotherapy and Pharmacology|2018Cited by 5